Background Multiple first-line immune checkpoint regimens are approved for advanced melanoma, yet no biomarker reliably guides their selection. LAG-3, an inhibitory checkpoint enriched on exhausted immune cells, may reflect tumor–immune state beyond PD-L1 and guide therapeutic decisions Methods We retrospectively analyzed Tempus platform data .